New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:33 EDTMU, APOL, INFY, PCYC, SVUOptions with decreasing implied volatility: APOL SVU INFY MU PCYC
News For APOL;SVU;INFY;MU;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 19, 2015
07:41 EDTPCYCPharmacyclics price target raised to $204 from $153 at Leerink
Subscribe for More Information
06:32 EDTPCYCPharmacyclics price target raised to $205 from $180 at Deutsche Bank
Subscribe for More Information
06:24 EDTPCYCPharmacyclics downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:15 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:08 EDTPCYCPharmacyclics upgraded to Buy from Neutral at Nomura
Subscribe for More Information
February 18, 2015
16:06 EDTPCYCPharmacyclics reaffirms 2015 product revenue guidance
Subscribe for More Information
16:04 EDTPCYCPharmacyclics reports Q4 EPS 96c, consensus 76c
Subscribe for More Information
15:35 EDTPCYCNotable companies reporting after market close
Subscribe for More Information
08:19 EDTMUMicron profitability can improve meaningfully, says Bernstein
Subscribe for More Information
05:13 EDTINFYInfosys announces multi-year, multimillion-dollar partnership with ABN AMRO
Subscribe for More Information
February 17, 2015
17:13 EDTMUPoint72 gives quarterly update on stakes
Subscribe for More Information
10:00 EDTMUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:56 EDTMUMicron rises, levels to watch
Subscribe for More Information
09:05 EDTPCYCPharmacyclics announces positive results from treatment with IMBRUVICA
Pharmacyclics announced that treatment with IMBRUVICA was associated with an 88% overall response rate, or ORR, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory, or R/R, high-risk chronic lymphocytic leukemia. These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival, or PFS, at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplant, a procedure in which stem cells from one person are transplanted to another. A second presentation during the BMT Tandem meeting highlighted data from five patients with R/R CLL who had undergone allo-HCT. The researchers concluded that these results support further study of IMBRUVICA in patients following allo-HCT, including those patients with chronic GVHD. Study PCYC 1129, a multicenter open--label Phase Ib/II study of IMBRUVICA in steroid--dependent or refractory chronic GVHD patients, has completed its Phase Ib without dose limiting toxicities and is now enrolling the Phase II portion at the recommended Phase II dose of 420 mg.
07:41 EDTMUMicron price target raised to $45 from $42 at Jefferies
Subscribe for More Information
07:10 EDTMUMicron upgraded to Outperform from Neutral at Macquarie
Macquarie upgraded Micron to Outperform with a $40 price target based on expectations memory medium-term pricing trends will remain stable given structural supply constraints, which could result in $5B in free-cash-flow in CY16.
February 16, 2015
10:49 EDTINFYInfosys to acquire automation technology firm Panaya for $200M
Subscribe for More Information
February 12, 2015
19:03 EDTMUMicron and Seagate partner to leverage storage solution technologies
Micron (MU) and Seagate (STX) announced a strategic agreement to deliver storage solutions. While initially focusing on next-generation SAS SSDs and strategic NAND supply, Micron and Seagate anticipate that this multi-year agreement will extend into future collaboration on enterprise storage solutions featuring Micron NAND flash memory.
15:17 EDTMUMicron to host analyst meeting
Analyst meeting to be held on February 13 at 10 am. Webcast Link
12:08 EDTMUStocks with call strike movement; TSLA MU
Tesla (TSLA) June 240 call option implied volatility decreased 6% to 41, Micron (MU) July 35 call option implied volatility decreased 2% to 39 according to IVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use